- First-line serplulimab versus placebo in combination with chemotherapy in PD-L1-positive oesophageal squamous cell carcinoma (ASTRUM-007): A randomised, double-blind, multicentre phase III studyHuang, J.; Song, Y.; Kou, X.; Tan, Z.; Zhang, S.; Sun, M.; Zhou, J.; Fan, M.; Zhang, M.; Song, Y.; Li, S.; Yuan, Y.; Zhuang, W.; Zhang, J.; Zhang, L.; Jiang, H.; Gu, K.; Ye, H.; Wang, Q.; Zhu, J.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.被引 1
- Updated results of first-line serplulimab versus placebo combined with chemotherapy in extensive-stage small cell lung cancer: An international multicentre phase III study (ASTRUM-005)Cheng, Y.; Han, L.; Wu, L.; Chen, J.; Sun, H.; Wen, G.; Ji, Y.; Dvorkin, M.; Shi, J.; Pan, Z.; Shi, J.; Wang, X.; Bai, Y.; Melkadze, T.; Pan, Y.; Min, X.; Viguro, M.; Kang, W.; Wang, Q.; Zhu, J.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
- First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (mESCC): Safety run-in results from the phase III LEAP-014 studySun, J-M.; Lin, C-Y.; Rojas, C.; Rivera, F.; Kwong, D.; Chen, M-H.; Zhang, Y.; Yamamoto, S.; Yu, L.; Shah, S.; Bhagia, P.; Shen, L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
会议论文
Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007)
5阅读
